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I. INTRODUCTION
This report is submitted, as required by Chapter 75, Section 43(1), on the activities of the
MassBiologics of the University of Massachusetts Medical School. This is the twentieth year
of such annual report.
The following sections provide the required infonnation as follows:
Part 2, Prior Fiscal Year (FY16) lnfonnation, as indicated by legislation, describes the patents
and licenses, agreements entered into, status of existing agreements, royalties and other
benefits, and expenditures, current assets and liabilities. This section includes two schedules:
(I) FY 16 Balance Sheet and (2) FY 16 Statement of Revenues and Expenditures and Other
Charges. -Included here is infonnation related to appropriated funds for the prior fiscal year,
as required by the legislation.
Part 3, Financial Plans, presents projected revenues and expenses. A three-year projection is 
included. 
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2. PRIOR FISCAL YEAR (FY16) INFORMATION
This section of the report presents the specilic information indicated in the legislation
related to the prior fiscal year (FY16: July I. 201 S - June 30, 2016). This is the twentieth
full year in which MassBiologics has operated w:ithin the University of Massachusetts.
The effective date of the transler to the University of Massachusetts was January I, 1997.
:t. Patents and Licensing 
MassBiologics has had two patents with claims allowed in FY16: 
Antibodies Against Clostridium Difficile Toxins and Uses Thereof 
I) 12/22/2015 United States Patent No. 9217029
2) 4/29/2016 India Patent No. 4482/CHENP/20IO
b, Agreements entered into 
MassBiologics extended its exclusive distribution agreement with Orifols Worldwide 
Operations Ltd. for the distribution of Tetanus and Diphtheria vaccine for a one year term 
ending June 30, 2017. 
MassBiologics entered into a series of research and collaboration agreements as follows: 
1) Antagen Pharmaceuticals Inc., for the development of a diphtheria antibody
effective 10/ l S/2015.
2) AbCellera Biologics Inc., to discover human antibodies against drug resistant
bacteria effective 3/14/2016.
3) Saureus Inc. for evaluation of a diagnostic for C. Difficile infection effective
4/12/2016.
4) University of Pennsylvania for plasmids to in AA V vector research effective
5/13/2016.
MassBiologics signed Service Agreements with 6 new clients (client names withheld per 
non-disclosure agreements) and secured repeat business from 4 existing clients, executed 
56 work order agreements that will generate $16,401,000 in new revenue, while continuing 
to build a pipeline of new potential customers for contract manufacturing 
services. MassBiologics South Coast Vector Manufacturing Center completed renovations 
to OMP manufacturing suites without interrupting its ability to execute client nonGMP 
development projects. 
... 
t. Grants and Contracts Awarded
DARPA Award of $11,411,276 was received from Defense ADV Research Projects 
Agency effective July I, 2013 through May 30, 2017. -$3,076,990 of funding was 
received in FYl6. 
R24 Grant- A no cost extension was received on Award ofSJ,332,331 - from National 
Institutes of Health through January 3 I ,  20 I 6. - An additional Award of $684,206 was 
received efiective January I, 2016 lhrough November 30, 2019. $265,914 of fonding was 
received in FY16. 
NIH Contract-Award of $5,378,361 was received from NIH-Nat'l lnst. of Allergy &
Infectious Disease effective September 29, 2013 through September 28, 2016. -
$1,806,876 of funding was received in FY 16. 
NIH Grant Award of $1,160,228 was received. from NIH-Nat'l Inst of Allergy & 
Infectious Disease effective May I, 2014 through April 30, 2017. -$351,788 of funding 
was received in FYl 6. 
MLSC Grant Award ofSS,000,000 was received from Massachusetts Life Sciences 
Center effective July I ,  2014 through June 30, 2016. $1,790,718 of funding was received 
in FY16. 
EOHED Grant Award ofSS,000,000 was received from MassWorks Infrastructure 
Program effective December 10, 2014 through June 30, 2016. $4,045,258 of funding was
received in FY16. 
NIH Grant Award of $89,827 was received from NIH-Nat'l Ctr Advancing Transitional 
Sciences effective April 1, 2014 through September 30, 2015 with a no cost extension 
through June 30, 2016. $2,387 of funding was received in FY16. 
NIH Grant Award of$103,163 was received from NIH-Nat'I Inst. of Neurological 
Disorders and Stroke effective September 20, 2015 through August 31, 2017. $74,526 of 
funding was received in FYI 6. 
CDC Contract - A ward of $190,260 was received from Antagen Pharmaceuticals, Inc. 
effective September 30, 2015 through September 29, 2017. $36,298 of funding was 
received in FY16. 
d. Status of existing agreements, royalties and other benefits
MassBiologics had the following major existing agreements in FYI 6.
Bristol-Meyers Squibb, fonnerly Medarex • a collaborative development agreement had
previously been signed April 17, 2002 with a public company (Medarex). This agreement
remains in place in support of MassBiologics' continued research.
s 
The Materials Cooperative Research and Development Agreement (M-CRADA) that was 
entered into January 30, 2004 with the CDC for Rabies was extended until January 30, 
2006. Subsequently, that agreement evolved into an Inter-institutional Agreement that was 
executed in August 2005. 
Merck Exclusive License Agreement April 20, 2009 for antibodies against C. Difficile. 
This agreement remains in place in support of continued clinical development of 
MassBiologics' proprietary CDiff antibodies. 
Serum Institute of India Ucense and Collaboration Agreement effective September 27, 
2006. This agreement remains in effect for the development and commercialization ofa 
rabies monoclonal antibody for the treatment of rabies. 
Ori fols Inc. Research Collaboration and License effective SI l 7/2014 for the development 
of a rabies monoclonal antibody therapeutic in North America. 
Grifols Inc. Distribution Agreement for Td vaccine in USA and Canada, effective 
7/1/2015. 
Voyager Therapeutics Inc. Strategic Collaboration Agreement for development and 
manufacturing of adeno associated virus (AA V) products, effective 10/20/2014. 
Life Technologies Corporation - Cell Line Services License agreement effective 
12/19/20 J 4; Commercial Production License effective 5/J /20 J 5; authorizes use of certain 
materials to support internal research and for use in services provided to external parties. 
Sale of Reagents: Reagents are by-products of the major manufacturing products of 
MassBiologics. MassBiologics makes these reagents available for research purposes. 
e. Revenues, expenditures, assets and liabilities
On the pages that follow, please find two schedules: (1) FY16 Statement of Revenues and
Expenditures and Other Charges, and (2) FY16 Balance Sheet. This information is
reviewed as part of the University of Massachusetts annual audit and is included as part of
comprehensive financial reports made to the University of Massachusetts' Board of
Trustees. Financial activities are also reported to the Office of the State Comptroller.
When reviewing these schedules, please note:
• State Appropriations I DPH represents the DPH appropriated fund support of the
�ffort at the Biologic Laboratories of$668,409. These funds only partially support
staff and provide the supplies and equipment used in the production of vaccine
which is distributed to residents of Massachusetts without charge. The vaccine
that is provided is Tetanus-Diphtheria vaccine (Td).
• License and Royalty Fees represents such payments received for CMV-IOIV, and
monoclonal antibodies to RSV and C difficile.
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The Plant Fund is lo cover lhe replacemenl of major equipment, essential lacility 
improvements necessary to meet FDA and other manufacturing license requirements. This 
account includes the cumulative capitalized equipment purchases and building 
improvements and a balance of unexpended lunds in reserve for planned equipment 
purchases and building improvements. fn FYl6, the planl fund continued to also be used to 
conclude the new lacility expenses. 
The core activities of MassBiologics remained consistent though FY 16. By way of review, 
in calendar year 2008, the MassBiologics received its Jicensure from the FDA to bring its 
new production facility on line. MassBiologics continued to manufacture clinical material 
in the new production facility to support its IND activities. 
The new production facility is located at the old Boston State Hospital location. This 
location was authorized by the legislature in July 2000 and opened October 2005. To 
support the costs of the new facility, Worcester City Campus Corporation borrowed in 
FY02 in reliance on its lease with the University of Massachusetts Medical School acting 
on behalf of MassBiologics. The plant fund represents payment of the lease payments 
supporting the bonds, as well as other capital costs associated with Worcester City Campus 
Corporation, the University of Massachusetts Medical School and the capital needs and 
operations of MassBiologics. 
Construction of Mattapan II was completed in the late spring of 20 t 0. The project was on 
time and within budget Mattapan ll was also occupied in this timeframe. 
To support the costs of Mattapan II, Worcester City Campus Corporation borrowed $3S 
million in FY 07 in reliance on its lease with the University of Massachusetts Medical 
School acting on behalf of the MassBiologics. 
It was detennined that MassBiologics would benefit from consolidating its operations to 
one campus by making facilities modifications to the Mattapan Campus. Modifications 
completed by June 2013 made it possible for MassBiologics to leave the Jamaica Plain 
Campus effective June 30, ending a 119 year tenancy at that campus. Commissioning and 
validation activities have been completed and the FDA has inspected and approved the 
manufacturing of T d vaccine. 
In fiscal 201 S it was determined that the MAB facility developed under the guidance of the 
UMass Dartmouth campus would be a better strategic fit if it were configured as a cGMP 
manufacturing resource for the development of vectored therapeutics under the operational 
control of MassBiologics. The previously identified grants totaling $10M from the MLSC 
and Mass Works were invested in the facility located at 1240 Innovation Way to support the 
cGMP requirements of vector manufacturing. In fiscal year 2016, the initial scope of work 
was completed on time and on budget with a few areas identified for future projects. The 
facility is now positioned to develop and manufacture cGMP requirements of vector 
manufacturing and continue to undergo the process to become validated. 
MassBiologics received a $2M business loan from the Greater Fall River Development in 
fiscal year 20 I 6. Payments will be repaid over the next five years. 
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University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expendltu,ws and Other Changes
For the Period July 1, 2015 Through June 30, 2016 
(Unaudited) 
CURRENT 
fYtm 
APPROPRIATED 
BUmi 
REVENUE AND OTHER ADDmONS: 
Product Sales 
Restricted Grants & Contracts
Stale Approprialions/OPH 
Ro�alty Fees and Interest 
Recovery of Indirect Costs 
Olher Income 
Total Revenue and Other Additions
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depredation 
Total Expenditures and Other DeductloM 
Net lncreaael(Decreaae) Before Transfers 
Nonmandatory Transfers 
TransfetS 
24,829,093 
11,450,755 
15,134,793 
641.en
121,n1
5t778,389 
18,723,153 
5,508,057 
29,142.749 
2,104,803 
55,478,782 
(2,700,373) 
(20,600,000) 
668,409 
668.409 
400,191 
108,652 
159,566 
668,409 
mt&.t 
24,829,093 
11,450,755 
668,409 
15,134,793 
841,9n 
121,n1 
53,446,798 
19,123,344 
5,616,709 
29,302,315 
2,104,803 
56,147,171 
(2,700,373) 
(20,600,000) 
Total Transfers (20,600,000) 0 • (20,600.000} 
Other Changes 
Excess of Restricted Receipts over Transfera to Revenue 
NET INCREASE(DECREASE) FOR THE VEAR 
Fund Balances at Beginning of Year (711/15) 
FUND BALANCES AT END OF YEAR
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(23.300,373) 
631898,007 
40._�7.� 0 
(23,300,373) 
63,898,007 
40.597,634
Assets 
cash 
Accounts Receivable 
Inventory 
Prepaid Expenses 
Buildings & Equipment 
Other Assets 
Totaf Assets 
LlablHtles 
Accounts Payable 
University of Massachusetts Blologlc Laboratories 
Balance Sheet 
As af June 30, 2016 
(Unaudited) 
CURRENT FUND PLANT FUND 
FY16 FY16 
7,358,366 3,090,776 
13,186,719 
8,604,658 
121,121 8,645 
12,525,518 
29,270,664 15.624,939
1,241,335 
Employee-Related Accruals 981,834 
Other Liabilities 75,0(J(L_� 2,000,000 
Total Uabllltles 2,298,169 2,000,000 
Fund Balances 26,972.695 13,624,939 
Total Llabllllles and Fund Balance 29,270,864 15,624.939 
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TOTAL 
FY16 
10,449,142 
13,186,719 
8,604,658 
129,766 
12,525,518 
44,895,803 
1,241,335 
981,834 
2,075,000 
4,298,169 
40.597,834 
44,895.803 
0 
Unfverslty of Massachusetts Blologlc laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2016 Ttvough June 30, 2017 
(Unaudited) 
REVl!NUE AND OTHER ADDmONS: 
Product Sales 
Restricted Grants & Conlracls 
Slate Appropriallons/DPH 
Royally Fees and Interest 
Recovery of Indirect Costs 
Olher Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decntaae) Befora Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(OECREASE) FOR THE VEAR 
Fund Balances at Beglnnln9 of Year (711/16) 
FUND BALANCES AT ENO OF YEAR 
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CURRENT APPROPRIATED 
FUND BUi1Ji TOTAL 
29,561,927 29,561,927 
5,744,687 5,744,687 
797,711 797,711 
18,220,388 18,220,388 
822,032 822,032 
1,255,210 1,255,210 
55,604,244 797:711 56,401,955 
19,558,892 405,732 19,964,624 
s,242,m 129,834 6,372,611 
26,439,404 262,145 26,701,549 
2,560,307 2,560,307 
54,801,380 797,711 55,699,091 
802,864 802,864 
0 0 0 
802,864 802,864 
40.597.634 40,597,634 
41,400.498 - - --41,400_.498
University of Massachuaetta Biologic Laboratories 
Statement of Revenues, Expendlll.ns and Other Changes 
For the Period July 1, 2017 Through June 30, 2018 
(Unaudited) 
CURRENT 
fW!l2 
APPROPRIATED 
FUNDS 
REVENUE AND OTHER ADDITIONS: 
Product Sales 32,905,350 
Restricted Grants & Contracts 5,513,922 
State Appropriations/OPH 540,566 
Royalty Fees and Interest 19,064.138 
Recovmy of Indirect Costs 652,876 
Other Income 755,210 
Total Revenue and Other Additions !;8,891,496 540.566 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 20,860,860 405,732 
Fringe Benefits 6,660,148 129,834 
Supplies and Services 25,429,077 5,000 
Depreciation 2,834,691 
Tot.al Expenditures and Other Deductions 55.784,776 540,566 
Net lncreaHl(Decraase) Before Transfers 3,106,720 
Nonmandatory Transfers 
Transfers 
Total Transfers 0 0 
Other Changes 
Excess of Restncted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 3,106,720 
Fund Balances at Beginning of Year (7/1117) 41,400,498 
TOTAL 
32.905,350 
5,513,922 
540,566 
19,064,138 
652,876 
755,210 
59,432:062
21,266,592 
6,789,982 
25,434,077 
2,834,691 
56.325,342 
3,106,720 
0 
3,108,720 
41.400.498 
FUND BALANCES AT END OF YEAR 44,507,218 0 . - �  44.507,218 
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University of Massachusetts Blologlc Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2018 Through June 30, 2019
(Unaudited) 
CURRENT 
.EWill 
APPROPRIATED 
FUNDS 
REVENUE AND OTHER ADDITIONS: 
Product Sales 36,466,360 
Restricted Grants & Contracts 4,551,727 
State Appropriallons/DPH 540,566 
Royalty Fees and Interest 20,189,138 
Recovery of Indirect Costs 482,251 
Other Income 755,210 
Total Revenue and Other Additions 62,444.686 540,586 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 22,681,848 405,732 
Fringe Benefits 7,239,615 129,834 
Supplies and Services 26,526,438 5,000 
OepteciaUon 3,112,587 
38,466,360 
4,551,727 
540,588 
20,189,138 
482.251 
755,210 
- 62.985,252 
23,087,580 
7,369,449 
26,531,438 
3,112 587 
Total Expenditures and Other DeductJons 59,560,488 540.566 60.101,054 
Net lncraase/{Decraaae) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Tnnsfans 
Other Changes 
Excess of Restricted Receipts over Transfers to Revenue 
N!T INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (711/18) 
FUND BALANCES AT END OF YEAR 
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2,884,198 2,884,198 
0 0 0 
2,884,198 2,884,198 
_ 4-4,507 218 44,507,218 
47.391416 0 47,391.416 
